Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa.

Hosuk RyouKorsuk SirinukunwattanaRuby WoodAlan AberdeenJens RittscherOlga K WeinbergRobert HasserjianOlga PozdnyakovaFrank PealeBrian HigginsPontus LundbergKerstin TrunzerClaire N HarrisonDaniel Royston

Published in: HemaSphere (2024)

Keyphrases

phase ii
bone marrow
clinical trial
open label
double blind
mesenchymal stem cells
placebo controlled
phase iii
single cell
replacement therapy
randomized controlled trial
study protocol
smoking cessation